The present disclosure is directed to the use of modified NK cells for immunotherapy in combination with an antibody, or antigen-binding fragment thereof, to induce an enhanced antibody-dependent cellular cytotoxicity (ADCC) effect.

This document relates to engineered immune cells comprising a FAP-CAR and a tumor-CAR with differential expressions, their use in the treatment of tumors expressing FAP, as well as methods and materials for the preparation thereof.

Provided herein are polypeptides, nucleic acids, and cells comprising antigen-binding domains that specifically bind to Solute Carrier Family 34 Member 2 (SLC34A2) or Transmembrane protease, serine 4 (TMPRSS4), and methods of use thereof. Also provided are polypeptides, systems, nucleic acids, and cells comprising priming receptors comprising an antigen-binding domain that specifically binds Solute Carrier Family 34 Member 2 (SLC34A2) and chimeric antigen receptors (CAR) comprising an antigen-binding domain that specifically binds to Transmembrane protease, serine 4 (TMPRSS4).

Provide are full human anti-FAP antibodies and variants thereof with further optimized CDR sequences. The new antibodies exhibited high affinity to the FAP protein and can be used to treat cancers and inflammatory conditions.

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcRI. Notably, CAR constructs with an intracellular domain of FcRI had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

Anti-V17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

Anti-V17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.